DiscoverNational Pharmaceutical Congress (NPC) PodcastS13 E01 Small Company, Seismic Impact: KYE Pharmaceuticals Redefines ADHD Treatment
S13 E01 Small Company, Seismic Impact: KYE Pharmaceuticals Redefines ADHD Treatment

S13 E01 Small Company, Seismic Impact: KYE Pharmaceuticals Redefines ADHD Treatment

Update: 2024-10-02
Share

Description

John McKendry, President and CEO of KYE, gives insights into the importance of operating within regulations, leadership in pharma, and new treatment and delivery options for ADHD.



Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S13 E01 Small Company, Seismic Impact: KYE Pharmaceuticals Redefines ADHD Treatment

S13 E01 Small Company, Seismic Impact: KYE Pharmaceuticals Redefines ADHD Treatment

Jeremy Visser